Christiane Engelbertz1, Eva Brand2, Manfred Fobker3, Dieter Fischer4, Hermann Pavenstädt2, Holger Reinecke5. 1. Division of Vascular Medicine, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany. Electronic address: christianemaria.engelbertz@ukmuenster.de. 2. Department of Nephrology, Hypertension, and Rheumatology, University Hospital Muenster, Muenster, Germany. 3. Center of Laboratory Medicine, University Hospital Muenster, Muenster, Germany. 4. Division for Cardiology, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany. 5. Division of Vascular Medicine, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany.
Abstract
BACKGROUND: Copeptin has turned out to give valuable prognostic information for future cardiovascular events. However, since its plasma concentration directly depends on renal function, the value of copeptin as a predictor for outcome also in patients with chronic kidney disease (CKD) is unknown. METHODS: In this single-center substudy of the German Coronary Artery Disease-REnal Failure (CAD-REF) registry, 301 patients with an angiographically diagnosed stenosis ≥50% in at least one major coronary vessel were included. Estimated glomerular filtration rate (eGFR) was determined using the MDRD formula and patients were classified according to their CKD stage. Copeptin concentrations were measured before initial angiography. Follow-up was performed at 180days, study endpoint was all-cause mortality. RESULTS: Of the 301 included patients, 35 (11.6%) patients had no CKD, 113 (37.5%) had CKD stage 1 or 2, 117 (38.9%) had CKD stage 3, and 36 (12.0%) had CKD stage 4 or 5. Copeptin was elevated (≥14pmol/L) in 81 (26.9%) patients and normal (<14pmol/L) in 220 (73.1%) patients. Copeptin values significantly increased with decreasing eGFR (p<0.001) and were strongly correlated with creatinine values (r=0.567, p<0.001). During 180days of follow-up, 15 patients (5.0%) died, 10 of them with elevated copeptin values. Multivariate Cox regression analysis showed that copeptin was the sole predictor for mortality (HRR 5.317 (95% CI 1.653-17.098), p=0.005), independent of serum creatinine. CONCLUSION: Elevated copeptin can be used as a valuable prognostic factor for intermediate-term mortality in patients with both coronary artery and renal disease.
BACKGROUND:Copeptin has turned out to give valuable prognostic information for future cardiovascular events. However, since its plasma concentration directly depends on renal function, the value of copeptin as a predictor for outcome also in patients with chronic kidney disease (CKD) is unknown. METHODS: In this single-center substudy of the German Coronary Artery Disease-REnal Failure (CAD-REF) registry, 301 patients with an angiographically diagnosed stenosis ≥50% in at least one major coronary vessel were included. Estimated glomerular filtration rate (eGFR) was determined using the MDRD formula and patients were classified according to their CKD stage. Copeptin concentrations were measured before initial angiography. Follow-up was performed at 180days, study endpoint was all-cause mortality. RESULTS: Of the 301 included patients, 35 (11.6%) patients had no CKD, 113 (37.5%) had CKD stage 1 or 2, 117 (38.9%) had CKD stage 3, and 36 (12.0%) had CKD stage 4 or 5. Copeptin was elevated (≥14pmol/L) in 81 (26.9%) patients and normal (<14pmol/L) in 220 (73.1%) patients. Copeptin values significantly increased with decreasing eGFR (p<0.001) and were strongly correlated with creatinine values (r=0.567, p<0.001). During 180days of follow-up, 15 patients (5.0%) died, 10 of them with elevated copeptin values. Multivariate Cox regression analysis showed that copeptin was the sole predictor for mortality (HRR 5.317 (95% CI 1.653-17.098), p=0.005), independent of serum creatinine. CONCLUSION: Elevated copeptin can be used as a valuable prognostic factor for intermediate-term mortality in patients with both coronary artery and renal disease.
Authors: Sherry G Mansour; Thomas G Martin; Wassim Obeid; Rachel W Pata; Karen M Myrick; Lidiya Kukova; Yaqi Jia; Petter Bjornstad; Joe M El-Khoury; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2019-08-14 Impact factor: 8.237
Authors: Razieh Hosseini; Farzaneh Montazerifar; Elham Shahraki; Mansour Karajibani; Ali Mohammad Mokhtari; Ali Reza Dashipour; Gordon A Ferns; Mohammad Jalali Journal: Biol Trace Elem Res Date: 2021-03-03 Impact factor: 3.738
Authors: R El-Damanawi; M Lee; T Harris; L B Cowley; S Bond; H Pavey; R N Sandford; I B Wilkinson; F E Karet Frankl; T F Hiemstra Journal: QJM Date: 2020-04-01